Role of Gut-Liver Axis in Non-Alcoholic Fatty Liver Disease: A Mini Review

Yaghmaei, Hessam; Taromiha, Amirmahdi; Nojoumi, Seyed Ali; Soltanipur, Masood; Shahshenas, Sina; Rezaei, Mahdi; Mirhosseini, Seyed Mohsen; Hosseini, Seyyed Mohammad; Siadat, Seyed Davar

doi:10.61186/ibj.4212

Volume 29, Issue 1 And 2 (1-2025) IBJ 2025, 29(1 And 2): 1-8 | Back to browse issues page

‎ 10.61186/ibj.4212

PMID: 40223320

Ethics code: Not applicable.

Mendeley

Zotero

RefWorks

Yaghmaei H, Taromiha A, Nojoumi S A, Soltanipur M, Shahshenas S, Rezaei M, et al . Role of Gut-Liver Axis in Non-Alcoholic Fatty Liver Disease: A Mini Review. IBJ 2025; 29 (1 and 2) :1-8
URL: http://ibj.pasteur.ac.ir/article-1-4212-en.html

Role of Gut-Liver Axis in Non-Alcoholic Fatty Liver Disease: A Mini Review

Hessam Yaghmaei

, Seyed Mohsen Mirhosseini

, Seyyed Mohammad Hosseini

, Seyed Davar Siadat ^*

Abstract:

Non-alcoholic fatty liver disease has emerged as a significant global health problem, mainly due to the increasing prevalence of obesity and metabolic syndrome. The gut microbiota plays an essential role in the development of NAFLD through the gut-liver axis. Dysbiosis of the GM is associated with the pathogenesis of NAFLD. Dietary choices and other lifestyle factors influence the composition of the GM and contribute to the development of NAFLD. At the phylum level, individuals with NAFLD show an increased level in Actinobacteria and Firmicutes, while Verrucomicrobia, Thermus, Proteobacteria, Lentiphaerae, and Fusobacteria are found to be decreased. Several genera, including Faecalibacterium and Akkermansia, exhibit alterations in NAFLD and are linked to disease progression. Modulating the GM through prebiotics, probiotics, or fecal microbiota transplantation represents a promising therapeutic strategy for NAFLD. This review summarizes the current understanding of GM changes in NAFLD, focusing on findings from both human and animal studies.

Keywords: Dysbiosis, Gastrointestinal microbiome, Microbiota, Non-alcoholic fatty liver disease

Full-Text [PDF 1260 kb]

Type of Study: Review Article | Subject: Molecular Microbiology

References

1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. [DOI:10.1002/hep.28431]

2. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55(7):434-8. [DOI:10.1016/S0025-6196(24)00530-5]

3. Oseini AM, Sanyal AJ. Therapies in non-alcoholic steatohepatitis (NASH). Liver Int. 2017;37(1):97-103. [DOI:10.1111/liv.13302]

4. Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a translational success story. Gut. 2015;64(5):830-41. [DOI:10.1136/gutjnl-2014-306842]

5. Zhou F, Zhou J, Wang W, Zhang XJ, Ji YX, Zhang P,et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta‐analysis. Hepatology. 2019;70(4):1119-33. [DOI:10.1002/hep.30702]

6. Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67(6):1265-73. [DOI:10.1016/j.jhep.2017.07.027]

7. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274-85. [DOI:10.1111/j.1365-2036.2011.04724.x]

8. Anderson EL, Howe LD, Jones HE, Higgins JPT, Lawlor DA, Fraser A. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. Plos one. 2015;10(10):e0140908. [DOI:10.1371/journal.pone.0140908]

9. Ashtari S, Pourhoseingholi MA, Zali MR. Non-alcohol fatty liver disease in Asia: Prevention and planning. World J Hepatol. 2015;7(13):1788-96. [DOI:10.4254/wjh.v7.i13.1788]

10. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-57. [DOI:10.1002/hep.29367]

11. Reinehr T. Lifestyle intervention in childhood obesity: changes and challenges. Nat Rev Endocrinol. 2013;9(10):607-14. [DOI:10.1038/nrendo.2013.149]

12. Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829-46. [DOI:10.1016/j.jhep.2017.05.016]

13. Bacchi E, Negri C, Targher G, Faccioli N, Lanza M, Zoppini G, et al. Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 Randomized Trial). Hepatology. 2013;58(4):1287-95. [DOI:10.1002/hep.26393]

14. Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, et al. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms. 2019;7(1):14. [DOI:10.3390/microorganisms7010014]

15. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Human gut microbes associated with obesity. Nature. 2006;444(7122):1022-3. [DOI:10.1038/4441022a]

16. Panasevich MR, Peppler WT, Oerther DB, Wright DC, Rector RS. Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification. Physiol Genomics. 2017;49(8):385-99. [DOI:10.1152/physiolgenomics.00012.2017]

17. Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab. 2017;25(5):1054-62. [DOI:10.1016/j.cmet.2017.04.001]

18. Clarke SF, Murphy EF, Nilaweera K, Ross PR, Shanahan F, O'Toole PW, et al. The gut microbiota and its relationship to diet and obesity: new insights. Gut Microbes. 2012;3(3):186-202. [DOI:10.4161/gmic.20168]

19. Le Roy T, Llopis M, Lepage P, Bruneau A, Rabot S, Bevilacqua C, et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut. 2013;62(12):1787-94. [DOI:10.1136/gutjnl-2012-303816]

20. Michail S, Lin M, Frey MR, Fanter R, Paliy O, Hilbush B, et al. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol Ecol. 2015;91(2):1-9. [DOI:10.1093/femsec/fiu002]

21. Del Chierico F, Nobili V, Vernocchi P, Russo A, De Stefanis C, Gnani D, et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. Hepatology. 2017;65(2):451-64. [DOI:10.1002/hep.28572]

22. Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57(2):601-9. [DOI:10.1002/hep.26093]

23. Raman M, Ahmed I, Gillevet PM, Probert CS, Ratcliffe NM, Smith S, et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2013;11(7):868-75. [DOI:10.1016/j.cgh.2013.02.015]

24. Jiang W, Wu N, Wang X, Chi Y, Zhang Y, Qiu X, et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep. 2015;5:8096. [DOI:10.1038/srep08096]

25. Schwiertz A, Taras D, Schäfer K, Beijer S, Bos NA, Donus C, et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity. 2010;18(1):190-5. [DOI:10.1038/oby.2009.167]

26. De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci USA. 2010;107(33):14691-6. [DOI:10.1073/pnas.1005963107]

27. Aranha MM, Cortez-Pinto H, Costa A, da Silva IBM, Camilo ME, de Moura MC, et al. Bile acid levels are increased in the liver of patients with steatohepatitis. Eur J Gastroenterol Hepatol. 2008;20(6):519-25. [DOI:10.1097/MEG.0b013e3282f4710a]

28. Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo‐Perez F, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63(3):764-75. [DOI:10.1002/hep.28356]

29. Turnbaugh PJ, Bäckhed F, Fulton L, Gordon JI. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe. 2008;3(4):213-23. [DOI:10.1016/j.chom.2008.02.015]

30. Da Silva HE, Teterina A, Comelli EM, Taibi A, Arendt BM, Fischer SE, et al. Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance. Sci Rep. 2018;8(1):1466. [DOI:10.1038/s41598-018-19753-9]

31. Aron-Wisnewsky J, Gaborit B, Dutour A, Clement K. Gut microbiota and non-alcoholic fatty liver disease: new insights. Clin Microbiol Infect. 2013;19(4):338-48. [DOI:10.1111/1469-0691.12140]

32. Wrzosek L, Miquel S, Noordine ML, Bouet S, Chevalier-Curt MJ, Robert V, et al. Bacteroides thetaiotaomicron and Faecalibacterium prausnitzii influence the production of mucus glycans and the development of goblet cells in the colonic epithelium of a gnotobiotic model rodent. BMC Biol. 2013;11:61. [DOI:10.1186/1741-7007-11-61]

33. Consolandi C, Turroni S, Emmi G, Severgnini M, Fiori J, Peano C, et al. Behçet's syndrome patients exhibit specific microbiome signature. Autoimmun Rev. 2015;14(4):269-76. [DOI:10.1016/j.autrev.2014.11.009]

34. Wong VWS, Tse CH, Lam TTY, Wong GLH, Chim AM-L, Chu WC-W, et al. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis-a longitudinal study. Plos one. 2013;8(4):e62885. [DOI:10.1371/journal.pone.0062885]

35. Alferink LJ, Radjabzadeh D, Erler NS, Vojinovic D, Medina‐Gomez C, Uitterlinden AG, et al. Microbiomics, Metabolomics, Predicted Metagenomics, and Hepatic Steatosis in a Population‐Based Study of 1,355 Adults. Hepatology. 2021;73(3):968-82. [DOI:10.1002/hep.31417]

36. Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fung SK, Fischer SE, et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology. 2013;58(1):120-7. [DOI:10.1002/hep.26319]

37. Pan X, Wen SW, Kaminga AC, Liu A. Gut metabolites and inflammation factors in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Sci Rep. 2020;10(1):8848. [DOI:10.1038/s41598-020-65051-8]

38. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457(7228):480-4. [DOI:10.1038/nature07540]

39. Armougom F, Henry M, Vialettes B, Raccah D, Raoult D. Monitoring bacterial community of human gut microbiota reveals an increase in Lactobacillus in obese patients and Methanogens in anorexic patients. Plos one. 2009;4(9):e7125. [DOI:10.1371/journal.pone.0007125]

40. Yuan J, Baker SS, Liu W, Alkhouri R, Baker RD, Xie J, et al. Endotoxemia unrequired in the pathogenesis of pediatric nonalcoholic steatohepatitis. J Gastroenterol Hepatol. 2014;29(6):1292-8. [DOI:10.1111/jgh.12510]

41. Sobhonslidsuk A, Chanprasertyothin S, Pongrujikorn T, Kaewduang P, Promson K, Petraksa S, et al. The association of gut microbiota with nonalcoholic steatohepatitis in Thais. Biomed Res Int. 2018;16:2018. [DOI:10.1155/2018/9340316]

42. Brahe LK, Astrup A, Larsen LH. Is butyrate the link between diet, intestinal microbiota and obesity‐related metabolic diseases? Obes Rev. 2013;14(12):950-9. [DOI:10.1111/obr.12068]

43. Munukka E, Pekkala S, Wiklund P, Rasool O, Borra R, Kong L, et al. Gut-adipose tissue axis in hepatic fat accumulation in humans. J Hepatol. 2014;61(1):132-8. [DOI:10.1016/j.jhep.2014.02.020]

44. Munukka E, Rintala A, Toivonen R, Nylund M, Yang B, Takanen A, et al. Faecalibacterium prausnitzii treatment improves hepatic health and reduces adipose tissue inflammation in high-fat fed mice. ISME J. 2017;11(7):1667-79. [DOI:10.1038/ismej.2017.24]

45. De Azevedo SJ, Addobbati C, Sandrin-Garcia P, Crovella S. Systemic lupus erythematosus: old and new susceptibility genes versus clinical manifestations. Curr Genomics. 2014;15(1):52-65. [DOI:10.2174/138920291501140306113715]

46. Schwenger KJ, Chen L, Chelliah A, Da Silva HE, Teterina A, Comelli EM, et al. Markers of activated inflammatory cells are associated with disease severity and intestinal microbiota in adults with non-alcoholic fatty liver disease. Int J Mol Med. 2018;42(4):2229-37. [DOI:10.3892/ijmm.2018.3800]

47. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A. 2013;110(22):9066-71. [DOI:10.1073/pnas.1219451110]

48. Cani PD. Human gut microbiome: hopes, threats and promises. Gut. 2018;67(9):1716-25. [DOI:10.1136/gutjnl-2018-316723]

49. Miura K, Ohnishi H. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(23):7381-91. [DOI:10.3748/wjg.v20.i23.7381]

50. Desai MS, Seekatz AM, Koropatkin NM, Kamada N, Hickey CA, Wolter M, et al. A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility. Cell. 2016;167(5):1339-53.e21. [DOI:10.1016/j.cell.2016.10.043]

51. Zhao S, Liu W, Wang J, Shi J, Sun Y, Wang W, et al. Akkermansia muciniphila improves metabolic profiles by reducing inflammation in chow diet-fed mice. J Mol Endocrinol. 2017;58(1):1-14. [DOI:10.1530/JME-16-0054]

52. Cani PD, Plovier H, Van Hul M, Geurts L, Delzenne NM, Druart C, et al. Endocannabinoids--at the crossroads between the gut microbiota and host metabolism. Nat Rev Endocrinol. 2016;12(3):133-43. [DOI:10.1038/nrendo.2015.211]

53. Ozkul C, Yalinay M, Karakan T, Yilmaz G. Determination of certain bacterial groups in gut microbiota and endotoxin levels in patients with nonalcoholic steatohepatitis. Turk J Gastroenterol. 2017;28(5):361-9. [DOI:10.5152/tjg.2017.17033]

Rights and permissions
	This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb

Iranian

Biomedical Journal